

# Sandor Schokker

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/8703627/publications.pdf>

Version: 2024-02-01

12  
papers

487  
citations

1163117

8  
h-index

1199594

12  
g-index

12  
all docs

12  
docs citations

12  
times ranked

691  
citing authors

#	ARTICLE	IF	CITATIONS
1	Neoadjuvant Chemoradiotherapy Combined with Atezolizumab for Resectable Esophageal Adenocarcinoma: A Single-arm Phase II Feasibility Trial (PERFECT). <i>Clinical Cancer Research</i> , 2021, 27, 3351-3359.	7.0	143
2	Survival Differences in Pediatric Pulmonary Arterial Hypertension. <i>Journal of the American College of Cardiology</i> , 2014, 63, 2159-2169.	2.8	123
3	Circulating tumor DNA quantity is related to tumor volume and both predict survival in metastatic pancreatic ductal adenocarcinoma. <i>International Journal of Cancer</i> , 2020, 146, 1445-1456.	5.1	67
4	Phase II Feasibility and Biomarker Study of Neoadjuvant Trastuzumab and Pertuzumab With Chemoradiotherapy for Resectable Human Epidermal Growth Factor Receptor 2-Positive Esophageal Adenocarcinoma: TRAP Study. <i>Journal of Clinical Oncology</i> , 2020, 38, 462-471.	1.6	44
5	Prognostic and predictive factors for overall survival in metastatic oesophagogastric cancer: A systematic review and meta-analysis. <i>European Journal of Cancer</i> , 2018, 103, 214-226.	2.8	28
6	Quality of Life During Palliative Systemic Therapy for Esophagogastric Cancer: Systematic Review and Meta-Analysis. <i>Journal of the National Cancer Institute</i> , 2020, 112, 12-29.	6.3	25
7	A phase II feasibility trial of neoadjuvant chemoradiotherapy combined with atezolizumab for resectable esophageal adenocarcinoma: The PERFECT trial. <i>Journal of Clinical Oncology</i> , 2019, 37, 4045-4045.	1.6	20
8	Circulating tumor DNA predicts outcome in metastatic gastroesophageal cancer. <i>Gastric Cancer</i> , 2022, 25, 906-915.	5.3	15
9	Development and validation of an LC-MS/MS method for simultaneous quantification of co-administered trastuzumab and pertuzumab. <i>MAbs</i> , 2020, 12, 1795492.	5.2	11
10	Phase I Dose Escalation Study with Expansion Cohort of the Addition of Nab-Paclitaxel to Capecitabine and Oxaliplatin (CapOx) as First-Line Treatment of Metastatic Esophagogastric Adenocarcinoma (ACTION Study). <i>Cancers</i> , 2019, 11, 827.	3.7	6
11	A phase Ib/II study of regorafenib and paclitaxel in patients with beyond first-line advanced esophagogastric carcinoma (REPEAT). <i>Therapeutic Advances in Medical Oncology</i> , 2022, 14, 175883592211091.	3.2	3
12	A Phase II Study Demonstrates No Feasibility of Adjuvant Treatment with Six Cycles of S-1 and Oxaliplatin in Resectable Esophageal Adenocarcinoma, with ERCC1 as Biomarker for Response to SOX. <i>Cancers</i> , 2021, 13, 839.	3.7	2